Experience

Theodorus Investment Funds

• Canada
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Senior Consultant

  • Jun 2020 - Present



Montréal InVivo

• Canada
• International Trade and Development
• 1 - 100 Employee

• Project Director of the Innovation Zone "Artificial Intelligence in Health"

  • Aug 2021 - Feb 2022

  I am in charge of a project to create an Innovation Zone in Montreal focused on Artificial Intelligence (AI) in health. This project, carried out jointly by Montreal InVivo and Montreal International, aims to mobilize all of the health AI players in Greater Montreal to accelerate the development and commercialization of innovations in AI applied to health and life sciences. I am in charge of a project to create an Innovation Zone in Montreal focused on Artificial Intelligence (AI) in health. This project, carried out jointly by Montreal InVivo and Montreal International, aims to mobilize all of the health AI players in Greater Montreal to accelerate the development and commercialization of innovations in AI applied to health and life sciences.



Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute

• Canada
• Research Services
• 200 - 300 Employee

• President and Scientific Director

  • Mar 2019 - Jun 2021

  Founded in 1967, the Montreal Clinical Research Institute (IRCM) is a non-profit organization that conducts fundamental and clinical biomedical research in addition to training high-level young scientists in an innovative technological environment. The Institute brings together about 450 people as well as 35 laboratories, which work in cancer, immunology, neuroscience, cardiovascular and metabolic diseases, systems biology and medicinal chemistry. The IRCM also operates a research clinic specialized in hypertension, cholesterol and diabetes as well as a research centre on rare and genetic diseases in adults. The IRCM is affiliated with Université de Montréal and associated with McGill University. Its clinic is affiliated with the Centre hospitalier de l’Université de Montréal (CHUM). The IRCM is supported by the Ministère de l’Économie et de l’Innovation (Quebec Ministry of Economy and Innovation). https://ircm.qc.ca/ Show less



Cancer Research Society

• Canada
• Research Services
• 1 - 100 Employee

• President and CEO

  • Jan 2017 - Feb 2019

  Max has joined the Cancer Research Society as President and CEO in January 2017. Founded in 1945, the Cancer Research Society is the first Canadian foundation entirely dedicated to funding research on all types of cancer. Over the course of its history, the CRS has supported thousands of our country's best scientific minds who have helped make important strides in the way we prevent, detect, and treat cancer. Since 2000, thanks to the generosity of donors across the country, the CRS distributed over $140 million in research grants across Canada. Max is bringing to the CRS his experience in research, fundraising and management. He has been given the mandate to grow and position the CRS as a leader among fundraising organizations in Canada as well as increasing awareness about the potential of innovative partnerships by leading research into new cooperative practices. www.cancerresearchsociety.ca Show less



NEOMED-LABS

• Canada
• Biotechnology Research
• 1 - 100 Employee

• Founder and CEO

  • Apr 2015 - Jan 2017

  NEOMED-LABS, a Canadian specialty company providing customized and high-throughput immune-monitoring for clinical vaccine and biologics development, is a spin-off from the GSK. Fully owned by the NEOMED Institute the facility is equipped with the latest platform technologies to conduct cutting-edge analyses of host responses to vaccines under GCLP conditions. Supported by an integrated system of laboratory robots and automated analyzers, the platforms allow high-throughput testing of clinical specimens to facilitate accelerated development of vaccines. LABS employs over 60 scientists and technicians. Max still has a seat on the Board of Directors of LABS. www.neomedlabs.com Show less



NEOMED Institute

• Montreal, Canada Area

• CEO

  • Nov 2012 - Jan 2017

  Max founded NEOMED in November 2012 as a not‐for‐profit organization whose mission is to bridge the gap between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with the creation of a vibrant and sustainable life science ecosystem. NEOMED operates two fully integrated research and development campuses in Montreal: one specializing in small molecule therapeutics, and the other specializing in the development of biologics and vaccines. Both facilities function as open‐access drug discovery hubs housing independent commercial businesses (30 independent companies employing more than 300 people) and providing a dynamic environment that stimulates collaboration, innovation, and creativity. NEOMED is jointly funded by our pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada. Max is still a sitting on the Board of Directors of NEOMED. www.neomed.ca Show less



CQDM

• Canada
• Biotechnology Research
• 1 - 100 Employee

• Founder and CEO

  • May 2008 - Nov 2012

  Founded in 2008 CQDM is a not-for-profit pharma-based consortium active in biopharmaceutical research whose mission is to fund the development of innovative tools and technologies to accelerate drug discovery. Unique in the world, CQDM’s business model is based on a collaborative approach where all stakeholders share the costs of biopharmaceutical research and benefit from its results. CQDM benefits from the financial support of 9 of the 12 largest pharmaceutical companies in the world, the Government of Quebec and the Government of Canada (Business Led-Networks of Centres of Excellence [BL-NCE] program). Since its inception, CQDM has raised $65 million, built an impressive portfolio of 60 outstanding technologies that impact biopharmaceutical research, and mobilized a national and international network of over 800 researchers from 74 different research institutions, universities, and small and medium-sized enterprises. www.cqdm.org Show less



Chronogen, Inc.

• Canada
• Research Services

• CEO

  • 2004 - 2007

  Chronogen, Inc., a biotechnology company, researched and developed therapeutics to fight oxidative-stress disorders in age-related diseases. It provided inhibitors for neurodegenerative diseases and atherosclerosis, compounds with cellular oxidative stress modulator activities, compounds for the treatment of pulmonary, hepatic, and renal fibrosis and hypolipidemic compounds for anti-atherosclerotic effects. The company was founded in 1998 and was based in Montreal, Canada. Chronogen, Inc., a biotechnology company, researched and developed therapeutics to fight oxidative-stress disorders in age-related diseases. It provided inhibitors for neurodegenerative diseases and atherosclerosis, compounds with cellular oxidative stress modulator activities, compounds for the treatment of pulmonary, hepatic, and renal fibrosis and hypolipidemic compounds for anti-atherosclerotic effects. The company was founded in 1998 and was based in Montreal, Canada.



Zambon

• Pharmaceutical Manufacturing
• 700 & Above Employee

• VP R&D

  • 1996 - 2003

  Vice-President R&D for Zambon Group in Italy responsible for all pre-clinical, clinical, and licensing activities of the group worldwide Founder of Z-cube, a corporate venture fund linked to Zambon Group. Vice-President R&D for Zambon Group in Italy responsible for all pre-clinical, clinical, and licensing activities of the group worldwide Founder of Z-cube, a corporate venture fund linked to Zambon Group.



Université Côte d'Azur

• France
• Higher Education
• 700 & Above Employee

• Professor, Director of the Master of Pharmacology

  • 1994 - 1996



Aster Biotechnologies

• La Gaude, France

• Founder and CEO

  • 1989 - 1996

  A start-up company, spun-off from INSERM developing immuno- tools and services for the Pharmaceutical Industry. Aster was specialized in Reproductive Biology, Immunochemistry and Molecular Biology. A start-up company, spun-off from INSERM developing immuno- tools and services for the Pharmaceutical Industry. Aster was specialized in Reproductive Biology, Immunochemistry and Molecular Biology.



INSERM

• France
• Research Services
• 700 & Above Employee

• Director, Unit 210

  • 1986 - 1989

  https://www.inserm.fr/

• Director of Research, Faculty of Medicine

  • 1978 - 1989

  https://www.inserm.fr/

• Director of Research, Unit 175

  • 1983 - 1986

  https://www.inserm.fr/

• Senior Researcher, Unit 175

  • 1978 - 1983

  https://www.inserm.fr/



Harvard Medical School

• United States
• Higher Education
• 700 & Above Employee

• Visiting Scientist

  • 1982 - 1983